SG11201704640SA - Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseases - Google Patents
Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseasesInfo
- Publication number
- SG11201704640SA SG11201704640SA SG11201704640SA SG11201704640SA SG11201704640SA SG 11201704640S A SG11201704640S A SG 11201704640SA SG 11201704640S A SG11201704640S A SG 11201704640SA SG 11201704640S A SG11201704640S A SG 11201704640SA SG 11201704640S A SG11201704640S A SG 11201704640SA
- Authority
- SG
- Singapore
- Prior art keywords
- immune
- prevention
- treatment
- monoclonal antibody
- antibody against
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201500223V | 2015-01-12 | ||
PCT/SG2016/050013 WO2016114720A1 (en) | 2015-01-12 | 2016-01-12 | Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201704640SA true SG11201704640SA (en) | 2017-07-28 |
Family
ID=56406141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201704640SA SG11201704640SA (en) | 2015-01-12 | 2016-01-12 | Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseases |
Country Status (6)
Country | Link |
---|---|
US (1) | US20170342136A1 (en) |
EP (1) | EP3244916A4 (en) |
JP (1) | JP6769970B2 (en) |
CN (1) | CN107106672B (en) |
SG (1) | SG11201704640SA (en) |
WO (1) | WO2016114720A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201503432SA (en) * | 2012-11-01 | 2015-05-28 | Agency Science Tech & Res | Monoclonal antibody against muramyl peptides |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2530957A1 (en) * | 1982-07-30 | 1984-02-03 | Anvar | PROCESS FOR SEPARATING OR PURIFYING A SLEEP-PROMOTING FACTOR FROM A BIOLOGICAL MEDIUM BY AN IMMUNOLOGICAL ANTIGEN-ANTIBODY REACTION |
TW200522932A (en) * | 2003-09-15 | 2005-07-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
WO2005072290A2 (en) * | 2004-01-23 | 2005-08-11 | Joslin Diabetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
WO2005115135A2 (en) * | 2004-04-09 | 2005-12-08 | The Regents Of The University Of California | Mouse model of crohn’s disease and a method to develop specific therapeutics |
US20060051353A1 (en) * | 2004-05-14 | 2006-03-09 | Jean-Frederic Colombel | Methods and compositions to evaluate antibody treatment response |
CN101039959A (en) * | 2004-06-30 | 2007-09-19 | 杜门蒂斯有限公司 | Compositions and methods for treating inflammatory disorders |
WO2008024075A1 (en) * | 2006-08-25 | 2008-02-28 | Agency For Science, Technology And Research | Modulators of candida hyphal morphogenesis and uses thereof |
CN103118691B (en) * | 2010-08-23 | 2016-08-24 | 康干细胞生物科技有限公司 | Prevent and treat immune disorders and the stem cell including processing of inflammatory diseases or the pharmaceutical composition of its culture with NOD2 agonist |
JP6400480B2 (en) * | 2012-02-15 | 2018-10-03 | ノヴォ ノルディスク アー/エス | Antibody that binds to peptidoglycan recognition protein 1 |
SG11201503432SA (en) * | 2012-11-01 | 2015-05-28 | Agency Science Tech & Res | Monoclonal antibody against muramyl peptides |
-
2016
- 2016-01-12 JP JP2017536799A patent/JP6769970B2/en active Active
- 2016-01-12 WO PCT/SG2016/050013 patent/WO2016114720A1/en active Application Filing
- 2016-01-12 SG SG11201704640SA patent/SG11201704640SA/en unknown
- 2016-01-12 US US15/538,077 patent/US20170342136A1/en not_active Abandoned
- 2016-01-12 EP EP16737617.7A patent/EP3244916A4/en active Pending
- 2016-01-12 CN CN201680005631.XA patent/CN107106672B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN107106672A (en) | 2017-08-29 |
JP6769970B2 (en) | 2020-10-14 |
EP3244916A1 (en) | 2017-11-22 |
US20170342136A1 (en) | 2017-11-30 |
JP2018502864A (en) | 2018-02-01 |
WO2016114720A1 (en) | 2016-07-21 |
CN107106672B (en) | 2021-06-22 |
EP3244916A4 (en) | 2018-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2500022I1 (en) | Therapeutic antibodies and their uses | |
IL258332A (en) | Antibody agents specific for human cd19 and uses thereof | |
IL256687B (en) | Isolated tau-binding antibody and use thereof in therapy and diagnosis | |
IL255278A0 (en) | Anti-ox40 antibodies and methods of use thereof | |
SG11201705585QA (en) | Anti-myostatin antibodies and methods of use | |
HK1259251A1 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
ZA201701920B (en) | Anti-human il-17 monoclonal antibodies and use thereof | |
IL286208A (en) | Humanized influenza monoclonal antibodies and methods of use thereof | |
SG11201708624YA (en) | Therapeutic antibodies and uses thereof | |
HUE059732T2 (en) | Humanized anti clever-1 antibodies and their use | |
ZA201805051B (en) | Egfl6 specific monoclonal antibodies and methods of their use | |
SG10202011023YA (en) | Dna monoclonal antibodies targeting il-6 and cd126 | |
SG11201704640SA (en) | Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseases |